Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors

LEBANON, N.H., Nov. 24, 2020 /PRNewswire/ — Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy’s North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.

“We are very fortunate to have Dennis’ counsel and unique skill set to help our team and board as we evolve our promising science towards creating cures for solid tumor cancer patients,” said Steven Yecies, Javelin’s Chief Executive Officer. “His track record and experience in moving promising science to ground-breaking therapies that help patients is a great match for Javelin’s needs. Dennis is a great example of the talent that we seek to surround ourselves with at Javelin and we look forward to his contributions. “

“Javelin has innovative and very promising immune-oncology technology and has assembled strong leadership in its management and on the board,” stated Dr. Langer. “I look forward to working with the company to advance the technology and make a difference for patients with solid cancers.”

More information about Dennis Langer is available at

About Javelin Oncology

Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts as well to create a services business to accelerate the science and use of precision immune medicine for others.

Learn more about Javelin Oncology at

Contact info
Steven Yecies
CEO, Javelin Oncology
[email protected]

SOURCE Javelin Oncology

Related Links

Source Article

Read More

X-37, LLC Appoints David Gluckman, M.D., to Board of Directors

X-37, LLC, an artificial intelligence-enabled drug discovery company, announced today that David Gluckman, M.D., has joined the company’s Board of Directors. Dr. Gluckman is Vice Chairman of Investment Banking and Global Head of Lazard’s Healthcare Group. He has been with Lazard since 1998, providing strategic and financial advice to senior executives and boards of directors at leading healthcare companies globally.

“We welcome Dr. Gluckman to X-37’s Board of Directors and look forward to benefitting from his experience and expertise in corporate strategy and finance as we advance our discovery and development programs against a variety of pharmaceutical targets,” said David Collier, M.D., CEO and cofounder of X-37. “Dr. Gluckman’s network and experience will be very valuable to X-37 as we seek to capitalize on these developments through partnerships with, and acquisitions by, major pharmaceutical companies.”

X-37 identifies high-value drug targets, generates novel drug leads against these targets using Atomwise’s AI platform for structure-based drug design, and develops each of these drug programs to a medically-relevant inflection point, where it can be acquired by or partnered with a major pharmaceutical company to be brought to market. X-37 makes use of an LLC structure permitting each drug development program to be housed in a separate virtual company under the parent LLC. This structure allows X-37 to divest individual drug development programs, while maintaining the parent company and team.

“X-37’s flexible business model allows these successful drug hunters to do what they do best, discover and develop novel drug candidates for important diseases,” said Dr. Gluckman. “I look forward to providing strategic guidance to the X-37 leadership team to help them capitalize their multiple therapeutic opportunities.”

Dr. Gluckman is a member of the Advisory Board of the Vagelos Program in Life Sciences and Management, jointly administered by the College of Arts and Sciences and the Wharton School at the University of Pennsylvania. He is a member of the Board of Trustees of the Hackley School. He is a member of the Leadership Council of AmeriCares and is a Lazard representative in The Council of Foreign Relations, Corporate Leader Program. Prior to joining Lazard, Dr. Gluckman was a practicing physician in Toronto, Canada. Dr. Gluckman is a licentiate of the Medical Council of Canada and a member of the College of Physicians and Surgeons of Ontario.

About X-37

X-37 is a pharmaceutical discovery and development company, which uses advanced artificial intelligence technology from Atomwise, Inc., to screen vast libraries of chemical compounds against high value pharmaceutical targets. X-37 develops these novel drug candidates under an innovative LLC structure which allows the sale or partnership of individual development programs in a simple and efficient manner. The team at X-37 possesses deep expertise in pharmaceutical development and the selection of pharmaceutical targets of high importance. For more information, please visit

View source version on


Jessica Yingling, Ph.D., Little Dog Communications Inc., +1 858-344-8091, [email protected]

Source Article

Read More

The Alliance for Regenerative Medicine Announces Election of 2021 Officers, Executive Committee, and Board of Directors

Washington, DC, Oct. 21, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, announced today the election of its 2021 Officers, Executive Committee, and Board of Directors.

The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. The committee and board are subject to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.

“We are pleased to welcome such an accomplished group of executives to the 2021 ARM board of directors,” said Janet Lambert, CEO of ARM. “As scientists, commercial leaders, and regulatory experts, the new members of the board will be instrumental in helping ARM and its members deliver transformative and potentially curative regenerative medicines to patients around the world.” 

ARM 2021 Officers:

Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics (Chairman)

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics (Vice Chairman)

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific (Secretary)

Devyn Smith, Ph.D. – COO, Sigilon Therapeutics (Treasurer)

ARM 2021 Executive Committee:
*new to the Executive Committee for 2021

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific 

* Miguel Forte, M.D., Ph.D. – CEO, Bone Therapeutics

Claudia Mitchell, MBA, Ph.D. – SVP, Product and Portfolio Strategy, Astellas Pharma

Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics 

Bob Smith, MBA – SVP, Global Gene Therapy Business, Pfizer Inc.

Devyn Smith, Ph.D. – COO, Sigilon Therapeutics

* Arthur Tzianabos, Ph.D. – President and CEO, Homology Medicines

* Christopher Vann – COO, Autolus Therapeutics 

ARM 2021 Board of Directors:
*new to the Board for 2021

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics

Ronald Bartek – Co-Founder and President, Friedreich’s Ataxia Research Alliance

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific

Bradley Campbell, MBA – President and COO, Amicus Therapeutics

Cindy Collins, MBA – President and CEO, Editas Medicine

* Maria Fardis, Ph.D., MBA – President and CEO, Iovance Biotherapeutics

Miguel Forte, M.D., Ph.D. – CEO, Bone Therapeutics

Jonathan Garen, M.S. – CBO, uniQure

* Bobby Gaspar, M.D., Ph.D. – CEO, Orchard Therapeutics

Michael Hunt, ACA – CFO, ReNeuron

Jerry Keybl, Ph.D. – Senior Director, Cell & Gene Therapy, MilliporeSigma

* Louise Rodino-Klapac, Ph.D. – SVP, Gene Therapy, Sarepta Therapeutics

Ann Lee, Ph.D. – SVP and Head of Cell Therapy Development & Operations, Bristol Myers Squibb

* Dave Lennon, Ph.D. – President, Novartis Gene Therapies

Bruce Levine, Ph.D. – Barbara and Edward Netter Professor in Cancer Gene Therapy, and Founding Director, Clinical Cell and Vaccine Production Facility, Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

John Maslowski, M.S. – President and CEO, Castle Creek Pharmaceuticals

Claudia Mitchell, MBA, Ph.D. – SVP, Product and Portfolio Strategy, Astellas Pharma

* Adora Ndu, PharmD,

Read More